Studies in the Area of Gene Therapy Reported from Sun Yat Sen University (Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5)
By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Fresh data on Biotechnology are presented in a new report. According to news reporting originating in Guangdong, People's Republic of China, by NewsRx journalists, research stated, "The objective of this study was to assess the clinical efficacy of genetically engineered recombinant human adenovirus type 5 (rhAd5) plus transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma (HCC). Data from two groups of patients with unresectable HCC were retrospectively reviewed."
The news reporters obtained a quote from the research from Sun Yat Sen University, "One group included 149 patients treated with rhAd5 injection, and the other included 150 control patients without gene therapy. Differences in short-term treatment effectiveness and adverse events were recorded and compared between the two groups. Our results indicated that for patients with higher tumor staging in the treatment group, the overall response rate and the disease control rate were higher than those in the control group, but not statistically significant (P > 0.05). The total progression free survival (PFS) and overall survival (OS) were significantly longer in the treatment group than the control group (240 vs. 196 days, P< 0.05; and 1,526 vs. 1,236 days, P = 0.000; respectively). The overall incidence rate of treatment-related adverse effects was similar (P > 0.05). No serious complications were observed."
According to the news reporters, the research concluded: "This study suggests that rhAd5 is a safe, effective gene therapy that prolongs the PFS and OS time of patients with unresectable HCC."
For more information on this research see: Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5. Medical Oncology, 2014;31(8):41-48. Medical Oncology can be contacted at: Humana Press Inc, 999 Riverview Drive Suite 208, Totowa, NJ 07512, USA. (Springer - www.springer.com; Medical Oncology - www.springerlink.com/content/1357-0560/)
Our news correspondents report that additional information may be obtained by contacting J. Dong, Sun Yat Sen UniversitySch Public Hlth, Dept. of Med Stat & Epidemiol, Guangzhou 510080, Guangdong, People's Republic of China. Additional authors for this research include W. Li, A.N. Dong, S.Y. Mao, L.J. Shen, S. Li, X. Gong and P.H. Wu (see also Biotechnology).
Keywords for this news article include: Guangdong, People's Republic of China, Asia, Adenovirus, Bioengineering, Biotechnology, Cancer Gene Therapy, Clinical Trials and Studies, Genetics, Hepatocellular Carcinoma, Oncology
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC